199 related articles for article (PubMed ID: 36359323)
1. Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma.
Zallocco L; Silvestri R; Ciregia F; Bonotti A; Marino R; Foddis R; Lucacchini A; Giusti L; Mazzoni MR
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359323
[TBL] [Abstract][Full Text] [Related]
2. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A
Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865
[TBL] [Abstract][Full Text] [Related]
3. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
4. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
6. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
Javadi J; Dobra K; Hjerpe A
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
[TBL] [Abstract][Full Text] [Related]
7. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
[TBL] [Abstract][Full Text] [Related]
8. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
[TBL] [Abstract][Full Text] [Related]
9. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.
Creaney J; Dick IM; Robinson BW
Curr Opin Pulm Med; 2015 Jul; 21(4):352-6. PubMed ID: 26016578
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
[TBL] [Abstract][Full Text] [Related]
13. Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.
Porcel JM; Esquerda A; Martínez-Alonso M; Bielsa S; Salud A
Medicine (Baltimore); 2016 Mar; 95(10):e3044. PubMed ID: 26962828
[TBL] [Abstract][Full Text] [Related]
14. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
[TBL] [Abstract][Full Text] [Related]
15. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.
Augeri S; Capano S; Morone S; Fissolo G; Giacomino A; Peola S; Drace Z; Rapa I; Novello S; Volante M; Righi L; Ferrero E; Ortolan E; Funaro A
Oncotarget; 2018 Apr; 9(32):22785-22801. PubMed ID: 29854315
[TBL] [Abstract][Full Text] [Related]
17. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.
Hegmans JP; Veltman JD; Fung ET; Verch T; Glover C; Zhang F; Allard WJ; T'Jampens D; Hoogsteden HC; Lambrecht BN; Aerts J
Technol Cancer Res Treat; 2009 Oct; 8(5):323-32. PubMed ID: 19754208
[TBL] [Abstract][Full Text] [Related]
18. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
19. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.
Mundt F; Heidari-Hamedani G; Nilsonne G; Metintas M; Hjerpe A; Dobra K
Biomed Res Int; 2014; 2014():419853. PubMed ID: 25147801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
